Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when XERS files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsXeris Biopharma to retire 69% of convertible debt through $23M note exchange for cash and stock
Filed June 11, 2026 · Period ending June 10, 2026 · ~1 min read
Key Changes
-
high
Company exchanging $23M of its 8% convertible notes due 2028 (69% of total outstanding) for cash equal to principal plus newly issued common stock, reducing debt from $33.5M to $10.5M
Item 8.01 verify on EDGAR → -
high
Stock portion of exchange will be priced using 21-day volume-weighted average starting June 11, 2026, meaning existing shareholders will face dilution from new share issuance
Item 8.01 verify on EDGAR → -
medium
Transaction expected to close around July 15, 2026, subject to customary conditions; company using existing cash to fund the $23M cash component
Item 8.01 verify on EDGAR → -
low
New shares issued in private placement to institutional investors without SEC registration, subject to transfer restrictions and not immediately tradable in public markets
Item 8.01 verify on EDGAR →
Summary
Xeris Biopharma is executing a significant debt reduction by exchanging roughly two-thirds of its outstanding convertible notes for a combination of cash and common stock. The company will pay $23 million in cash (using existing liquidity) and issue new shares priced based on a 21-day trading average to retire notes that currently carry an 8% interest rate and mature in 2028.
This move strengthens the balance sheet by eliminating $23 million in debt obligations and associated interest expense, but comes at the cost of shareholder dilution. Retail investors should note that while debt reduction is generally positive for financial flexibility, the stock component means existing ownership stakes will be diluted.
The exact number of new shares won't be known until the 21-day pricing period completes. Watch for the company's disclosure around mid-July of the final share count issued and any updates on how the reduced debt burden affects their cash runway and operating plans. The remaining $10.5 million in convertible notes stays outstanding until 2028.
Section-by-Section Diff
Event · Item 3.02 — Unregistered Sales of Equity Securities
Item 3.02 — Unregistered Sales of Equity Securities filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
The closing of the Exchange is expected to occur on or about July 15, 2026, subject to customary closing conditions.
The transaction is expected to close around July 15, 2026, subject to standard closing conditions. This gives investors a timeline for when the debt reduction and share dilution will occur.
Event · Item 8.01 — Other Events
Xeris Biopharma announced entry into Exchange Agreements via press release; specific terms and transaction details not disclosed in 8-K body.
Added in current filing · verify on EDGAR →
On June 11, 2026, the Company issued a press release announcing entry into the Exchange Agreements.
The company has entered into Exchange Agreements and announced this via press release. The 8-K references Exchange Consideration and expected timing but does not provide specific terms, counterparties, or financial details in the body text. The full details are presumably in the attached press release (Exhibit 99.1).
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 11, 2026 · How we verify